Materials and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010; 127: 2893-2917
- Projections of the cost of cancer care in the United States: 2010-2020.J Natl Cancer Inst. 2011; 103: 117-128
- Body-surface area-based chemotherapy dosing: appropriate in the 21st century?.J Clin Oncol. 2012; 30: 3896-3897
- Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.J Natl Cancer Inst. 2009; 101: 1543-1552
- Will we ever be ready for blood level-guided therapy?.J Clin Oncol. 2008; 26: 2078-2079
- Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.Clin Colorectal Cancer. 2011; 10: 203-206
- Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.Ther Drug Monit. 2009; 31: 688-694
- Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.J Clin Oncol. 2008; 26: 2099-2105
- Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.Clin Colorectal Cancer. 2012; 11: 263-267
- Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.Expert Rev Pharmacoecon Outcomes Res. 2005; 5: 153-162
- A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.Am J Clin Oncol. 2009; 32: 49-55
- R: A Language and Environment for Statistical Computing.2013 (Available at: http://web.mit.edu/r_v3.0.1/fullrefman.pdf)
- Markov models in medical decision making a practical guide.Med Decis Making. 1993; 13: 322-338
- FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol. 2004; 22: 229-237
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.J Clin Oncol. 2008; 26: 3523-3529
Engauge Digitizer - Digitizing software. Available at: http://digitizer.sourceforge.net. Accessed June 15, 2014.
- Advances in Statistical Methods for the Health Sciences.Springer, Boston2007
- United States life tables, 2007.Natl Vital Stat Rep. 2011; 59: 1-60
- Quality of life in survivors of colorectal carcinoma.Cancer. 2000; 88: 1294-1303
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.Lancet Oncol. 2013; 14: 29-37
- Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.Cancer. 2007; 109: 1082-1089
Centers for Disease Control and Prevention. FastStats Homepage. Available at: http://www.cdc.gov/nchs/fastats/. Accessed June 15, 2014.
CMS.gov. Centers for Medicare & Medicaid Services. 2013 ASP Drug Pricing Files. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2013ASPFiles.html. Accessed June 15, 2014.
CMS.gov. Centers for Medicare & Medicaid Services. Medicare physician fee schedule. Available at: http://www.cms.gov/apps/physician-fee-schedule/. Accessed September 1, 2013.
- A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.Value Health. 2011; 14: 836-845
- Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.Pharmacogenomics J. 2013; 13: 389-395
- Should DPD analysis be required prior to prescribing fluoropyrimidines?.Eur J Cancer. 2007; 43: 1011-1016
- Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.Breast Cancer Res Treat. 2012; 133: 1115-1123
- A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K..Br J Cancer. 2013; 108: 2250-2258
- Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.J Med Econ. 2013; 16: 30-40
- Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.J Natl Cancer Inst. 2012; 104: 1785-1795